Mestag Therapeutics Licenses Novel Inflammatory Disease Target to Johnson & Johnson

Cambridge-based Mestag Therapeutics, a pioneering biotech firm focused on fibroblast-immune interactions, has announced that a novel target from its RAFT (Reversing Activated Fibroblast Technology) platform has been exclusively licensed by Johnson & Johnson. This deal follows a multi-year target discovery collaboration that commenced in 2021. The licensed target, whose specifics remain undisclosed, underscores the capabilities of Mestag's RAFT platform in identifying key drivers of inflammatory diseases through sophisticated genetic screening techniques. Under the terms of the agreement, Johnson & Johnson will be responsible for the development and commercialization of therapeutics directed at the licensed target, while Mestag stands to gain future milestone payments. Founded by leading researchers from prestigious institutions, Mestag is backed by SV Health Investors and other major venture capital entities. Mestag continues to expand its therapeutic pipeline across oncology and inflammatory disease domains, thereby pushing the frontier in fibroblast-immune biology.